What Does This Emerging Trend Hold for Branded Agents? Asthma and chronic obstructive pulmonary disease (COPD) are chronic diseases of the airways affecting millions of Americans and representing…
Amid Substantial Unmet Need, What Clinical Improvements Do Neurologists and Payers Expect of Novel Symptomatic and First-to-Market Disease-Modifying Therapies? Alzheimer’s disease (AD) will pose…
Hepatitis C virus (HCV) chronic infections are a leading cause of advanced liver disease and hepatocellular carcinoma. The first-generation protease inhibitors were a major advancement in the…
In a Market Dominated by Well-Entrenched, Effective Psychostimulants, What Do Physicians and Payers Identify as Areas for Differentiation? Attention-deficit/hyperactivity disorder (ADHD) is a…
For Neurologists and Payers, What Opportunities Still Exist for Novel Disease-Modifying Therapies in an Increasingly Crowded Market? The relapsing-remitting multiple sclerosis (RR-MS) therapy…
Takeda’s Entyvio (vedolizumab) gained FDA approval in May 2014; the drug launched in the United States in June 2014. This report measures the impact of this novel agent on the moderate to severe…
A Survey of Non-interventional Cardiologists and Managed Care Organization Pharmacy and Medical Directors Atherosclerosis refers to the thickening of arterial walls due to deposition of plaque; it…
What Key Attributes Do Oncologists and Payers Believe Will Differentiate Emerging Therapies? The first-line chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) market is becoming…
What Advantages Do Surveyed Oncologists and Payers Believe Emerging Therapies Must Offer to Gain Traction in This Increasingly Competitive Market? In recent years, several new, high-priced…
How Are Payers Reacting to Elevated Costs and How Will the Cost Trend Impact Specific Brands? The nation’s healthcare payers are using multilayered cost and utilization control strategies to rein…
What Are Physician and Payer Expectations as New Mechanisms of Action Transform the Market Landscape? Significant opportunity remains for therapies to treat moderate to severe ulcerative colitis (…
LaunchTrends: Anoro Ellipta Wave 2 is the second of a three-wave report series designed to track the postlaunch awareness, trial, and usage of Anoro Ellipta among pulmonologists for the treatment…
How Are Payers Responding to High-Cost Therapies on Their Exchange-Based Plans? The Affordable Care Act (ACA) has expanded access to insurance coverage to millions and has reformed health insurance…
Biosimilars are potentially disruptive to the pharmaceutical industry; the biosimilars sector not only allows extremely lucrative commercial opportunities for biosimilar companies but also poses an…
In 2011, GlaxoSmithKline’s Benlysta became the first biological treatment ever approved for systemic lupus erythematosus (SLE) and the first drug approved for SLE in more than 50 years. However,…
